ArticleCancer research2010
Interleukin-15 and its receptor augment dendritic cell vaccination against the neu oncogene through the induction of antibodies partially independent of CD4 help.
Article in Cancer research, 2010. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 26 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
26 citing papers in PubMed, 1 synthesis or guideline pooled it, 45 citations in OpenAlex.
- Intercepting Premalignant, Preinvasive Breast Lesions Through Vaccination.Frontiers in immunology · 2021Pooled it
- An Oncolytic Virus Expressing IL15/IL15Rα Combined with Off-the-Shelf EGFR-CAR NK Cells Targets Glioblastoma.Cancer research · 2021Article
- Immunobiology of the IL-15/IL-15Rα complex as an antitumor and antiviral agent.Cytokine & growth factor reviews · 2017Review
- Dying to protect: cell death and the control of T-cell homeostasis.Immunological reviews · 2017Review
- Chemotherapy and immunotherapy: A close interplay to fight cancer?Oncoimmunology · 2016Review
- IL-15 temporally reorients IL-10 biased B-1a cells toward IL-12 expression.Cellular & molecular immunology · 2016Article
- Transpresentation of interleukin-15 by IL-15/IL-15Rα mRNA-engineered human dendritic cells boosts antitumoral natural killer cell activity.Oncotarget · 2015Article
- Combined therapy with CTL cells and oncolytic adenovirus expressing IL-15-induced enhanced antitumor activity.Tumour biology : the journal of the International Society for Oncodevelopmental Biology and Medicine · 2015Article
- Interleukin-15 is required for immunosurveillance and immunoprevention of HER2/neu-driven mammary carcinogenesis.Breast cancer research : BCR · 2015Article
- Dendritic cell-derived interleukin-15 is crucial for therapeutic cancer vaccine potency.Oncoimmunology · 2014Article
- The new normal: immunomodulatory agents against sepsis immune suppression.Trends in molecular medicine · 2014Review
- Vaccination with tumor cells expressing IL-15 and IL-15Rα inhibits murine breast and prostate cancer.Gene therapy · 2014Article
- Oral vaccination with adeno-associated virus vectors expressing the Neu oncogene inhibits the growth of murine breast cancer.Molecular therapy : the journal of the American Society of Gene Therapy · 2013Article
- Histological evaluation of intratumoral myxoma virus treatment in an immunocompetent mouse model of melanoma.Oncolytic virotherapy · 2013Article
- Preclinical HER-2 Vaccines: From Rodent to Human HER-2.Frontiers in oncology · 2013Article
- IL-15 augments antitumoral activity of an ErbB2/HER2 cancer vaccine targeted to professional antigen-presenting cells.Cancer immunology, immunotherapy : CII · 2012Article
- Strategies to use immune modulators in therapeutic vaccines against cancer.Seminars in oncology · 2012Review
- Liver gene transfer of interkeukin-15 constructs that become part of circulating high density lipoproteins for immunotherapy.PloS one · 2012Article
- Interleukin-15 biology and its therapeutic implications in cancer.Trends in pharmacological sciences · 2012Review
- IL-15 ex vivo overcomes CD4+ T cell deficiency for the induction of human antigen-specific CD8+ T cell responses.Journal of leukocyte biology · 2011Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 3 institutions in 2 countries.
Funding
Abstract
Interleukin-15 (IL-15) stimulates the diffrentiation and proliferation of T, B, and natural killer cells; enhances CD8(+) cytolytic T-ceII activity; helps maintain CD44(hi)CD8(+) memory T cells; and stimulates immunoglobulin synthesis by B cells. IL-15 is trans-presented to effector cells by its receptor, IL-15Ralpha, expressed on dendritic cells (DC) and monocytes. We examined the antitumor effect of adenoviral-mediated gene transfer of IL-15 and IL-15Ralpha to augment a DC vaccine directed against the NEU (ErbB2) oncoprotein. Transgenic BALB-neuT mice vaccinated in late-stage tumor development with a DC vaccine expressing a truncated NEU antigen, IL-I5, and its receptor (DC(Ad.Neu+Ad_mIL-15+Ad.mlL-15Ralpha)) were protected from mammary carcinomas, with 70% of animals tumor-free at 30 weeks compared with none of the animals vaccinated with NEU alone (DC(Ad.Neu)). The combination of neu, IL-15, and IL-15Ralpha gene transfer leads to a significaintly greater anti-NEU antibody response compared with mice treated with DC(Ad.Neu) or DC(Ad.Neu) combined with either IL-15 (DC(Ad.Neu+Ad.mlL-15)) or lL-15Ralpha (DC(Ad.Neu+Ad.mlL-15Ralpha)). The antitumor effect was antibody mediated and involved modulation of NEU expression and signaIing. Depletion of CD4(+) cells did not abrogate the antitumor effect of the vaccine, nor did it inhibit the induction of anti-NEU aritibodies. Coexpression of IL-15 and IL-15Ralpha in an anticancer vaccine enhanced immune responses against the NEU antigen and may overcome impaired CD4(+) T-helper function.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.